Retraction Note: Safety and efficacy of dapoxetine in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study(Neuropsychopharmacology, (2008), 33, (1259–1265), 10.1038/sj.npp.1301500);Safety and efficacy of dapoxetine in the treatment of premature ejaculation: A double-blind, placebo-controlled, fixed-dose, randomized study

Neuropsychopharmacology

Volumn 33, Issue 6, 2008, Pages 1259-1265

  Safarinejad, Mohammad R ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Dapoxetine; Premature ejaculation; Serotonin; Sexual dysfunction; Treatment

Indexed keywords

DAPOXETINE;

ANAMNESIS; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HEADACHE; HUMAN; INSOMNIA; NAUSEA; OUTCOME ASSESSMENT; PHYSICAL EXAMINATION; PREMATURE EJACULATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEXUAL INTERCOURSE; SEXUAL SATISFACTION; STUDENT T TEST; VOMITING;

EID: 42049112050     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/s41386-023-01550-2     Document Type: Erratum

References (39)

1. Ahlenius S, Larsson K, Svensson L, Hjorth S, Carlsson A, Lindberg P et al (1981). Effects of a new type of 5-HT receptor agonist on male rat sexual behavior. Pharmacol Biochem Behav 15: 785-792.
2. Baldesarani RJ, Mars E (2003). Fluoxetine and side effects. Arch General Psychiatry 47: 191-192.
3. Byers ES, Grenier G (2003). Premature or rapid ejaculation: heterosexual couples' perceptions of men's ejaculatory behavior. Arch Sex Behav 32: 261-270.
4. Dresser M, Lindert K, Lin D, Gidwani S, Gupta SK, Modi NB (2004). Pharmacokinetics of single and multiple escalating doses of dapoxetine in healthy volunteers [abstract]. Clin Pharmacol Ther 75: 113.
5. Feret B (2005). Focus on dapoxetine: a novel, fast-acting serotonin reuptake inhibitor. Formulary 40: 227-230.
6. Fisher E (1986). Common sexual problems in general practice. Aust Fam Physician 15: 43-47.
7. Fleiss J (1986). The Design and Analysis of Clinical Experiments. John Wiley & Sons Inc.: New York, NY, pp 49-51.
8. Frink MC, Hennies HH, Englberger W, Haurand M, Wilffert B (1996). Influence of tramadol on neurotransmitter systems of the rat brain. Arzneimittelforschung 46: 1029-1036.
9. Gengo PJ, View M, Giuliano F, McKenna KE, Chester A, Lovenberg T (2005). Monoaminergic transport binding and inhibition profile of dapoxetine, a medication for the treatment of premature ejaculation. J Urol 173(Suppl): 239. (abstract 878).
10. Hellstrom WJ, Althof S, Gittelman M, Steidle C, Ho KF, Kell S et al (2005). Dapoxetine for the treatment of men with premature ejaculation (PE): dose-finding analysis. J Urol 173(Suppl): 238 (abstract 877).
11. Hellstrom W, Gittelman M, Althof S, Ho KF, Kell S (2004). Dapoxetine HCl for the treatment of premature ejaculation: a phase II, randomized, double-blind, placebo-controlled study. J Sex Med 1(Suppl): 59. (abstract 097).
12. Hillegaart V, Ahlenius S (1998). Facilitation and inhibition of male rat ejaculatory behaviour by the respective 5-HT1A and 5-HT1B receptor agonists. Brit J Pharmacol 125: 1733-1743.
13. Kaplan HS (1974). The New Sex Therapy: Active Treatment of Sexual Dysfunctions. Brunner/Maazel: New York.
14. Kim SW, Paick JS (1999). Short-term analysis of the effects of as needed use of sertraline at 5 pm for the treatment of premature ejaculation. Urology 54: 544-547.
15. Laumann EO, Paik A, Rosen RC (1999). Sexual dysfunction in the United States: prevalence and predictors. JAMA 281: 537-544.
16. Manasia P, Pomerol J, Ribe N, Gutierrez del Pozo R, Alcover Garcia J (2003). Comparison of the efficacy and safety of 90 vs 20 mg fluoxetine in the treatment of premature ejaculation. J Urol 170: 164-165.
17. Masters WH, Johnson VE (1970). Human Sexual Inadequacy. Little, Brown: Boston, pp 92-142.
18. McMahon CG (1998). Treatment of premature ejaculation with sertraline hydrochloride: a single-blind placebo controlled crossover study. J Urol 159: 1935-1938.
19. McMahon CG (2004). Pharmacological treatment of ejaculatory disorders. J Sex Med (Suppl 1): 19-21.
20. Modi NB, Dresser MJ, Simon M, Lin D, Desai D, Gupta S (2006). Single- and multiple-dose pharmacokinetics of dapoxetine hydrochloride, a novel agent for the treatment of premature ejaculation. J Clin Pharmacol 46: 301-309.
21. Molewijk HE, van der Heyden JAM, Olivier B (1989). Lower lip retraction is selective mediated by activation of the 5-HT1A receptor. Eur J Neurosci 214(Suppl 2): 121.
22. Perelman MA, McMahon CG, Barada JH (2004). Evaluation and treatment of the ejaculatory disorders. In: Lue T (ed). Atlas of Male Sexual Dysfunction. Current Medicine, Inc.: Philadelphia, PA. pp 127-157.
23. Pryor JL, Althof SE, Steidle C, Rosen RC, Hellstrom WJ, Shabsigh R, Dapoxetine Study Group et al (2006). Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet 9: 929-937.
24. Remy L (1986). The effect of selective 5HT reuptake inhibitors on 5-methoxy-N,N-dimethyltriptamine induced ejaculation in the rat. Br J Pharmacol 87: 639-648.
25. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A (1997). The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 49: 822-830.
26. Rowland DL, Cooper SE, Schneider M (2001). Defining premature ejaculation for experimental and clinical investigations. Arch Sex Behav 30: 235-253.
27. Sae Chul K, Kyung S (1998). Efficacy and safety of fluoxetine, sertraline and clomipramine in patients with premature ejaculation: a double-blind, placebo controlled study. J Urol 159: 425-427.
28. Safarinejad MR (2006). Comparison of dapoxetine vs paroxetine in patients with premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Clin Neuropharmacol 29: 243-252.
29. Safarinejad MR, Hosseini SY (2006). Safety and efficacy of citalopram in the treatment of premature ejaculation: a double-blind placebo-controlled, fixed dose, randomized study. Int J Impot Res 18: 164-169.
30. Spector IP, Carey MP (1990). Incidence and prevalence of sexual dysfunctions. A critical review of the empirical literature. Arch Sex Behav 19: 389-408.
31. Symonds T, Roblin D, Hart K, Althof S (2003). How does premature ejaculation impact a man's life? J Sex Marital Ther 29: 361-370.
32. Szele FG, Murphy DL, Garrick NA (1988). Effects of fenfluramine, m-chlorophenylpiperazine and other serotonin-related agonists and antagonists on penile erections in non-human primates. Life Sci 43: 1297-1303.
33. Waldinger MD (2003). Towards evidence-based drug treatment research on premature ejaculation: a critical evaluation of methodology. Int J Impot Res 15: 309-313.
34. Waldinger MD (2004). Life-long premature ejaculation: from authority based to evidence based medicine. Br J Urol, Int Update Series 93: 201-207.
35. Waldinger MD, Berendsen HHG, Blok BFM, Olivier B, Holstege G (1998a). Premature ejaculation and serotonergic antidepressant-induced delayed ejaculation: the involvement of the serotonergic system. Behav Brain Res 92: 111-118.
36. Waldinger MD, Hengeveld MW, Zwinderman AH (1994). Paroxetine treatment of premature ejaculation: a double-blind, randomised, placebo-controlled study. Am J Psychiatry 151: 1377-1379.
37. Waldinger MD, Hengeveld MW, Zwinderman AH, Olivier B (1998b). Effect of SSRI antidepressants on ejaculation: a double-blind, randomised, placebo controlled study with fluoxetine, fluvoxamine, paroxetine and sertraline. J Clin Psychopharm 18: 274-281.
38. Waldinger MD, Zwinderman AH, Olivier B (2001). Antidepressants and ejaculation: a double-blind, randomized, placebo-controlled, fixed-dose study with paroxetine, sertraline, and nefazodone. J Clin Psychopharm 21: 293-297.
39. Waldinger MD, Zwinderman AH, Schweitzer DH, Olivier B (2004a). Relevance of methodological design for the interpretation of efficacy of drug treatment of premature ejaculation: a systematic review and meta-analysis. Int J Impot Res 16: 369-381.